FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-028

OMB Number:	3235-0287
Estimated average bure	den
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  ZDRAVESKI ZORAN						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Magenta Therapeutics, Inc. [ MGTA ]									Check	all app	licable)		Owner
(Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC. 50 HAMPSHIRE STREET						3. Date of Earliest Transaction (Month/Day/Year) 12/24/2019									X Officer (give title below) Other (specify below)  See Remarks				
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution D		n Date,	3. Transaction Code (Instr. 8)						4 and Secu Bend Own		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	.	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)
Common Stock 12/24					/2019				S <sup>(1)</sup>	S <sup>(1)</sup> 7,9		2 D \$		\$10	6 <sup>(2)</sup>	128,009		D	
		Та	able II - D )								sed of, onvertib					vned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Disport of (D	of		exercision Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)					9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code V		v	(A)	(D)	Date Expirat Exercisable Date		Expiration Date	Title	Amount or Number of Title Shares								

## **Explanation of Responses:**

- 1. This trade is pursuant to an active 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$16.00 to \$16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

### Remarks:

Secretary and Chief Legal Officer

/s/Zoran Zdraveski

\*\* Signature of Reporting Person Date

12/26/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.